Increased Risk for Ipsilateral Breast Tumor Recurrence in Invasive Lobular Carcinoma after Accelerated Partial Breast Irradiation Brachytherapy

CONCLUSIONS: These results show that APBI is an effective treatment for patients with invasive breast cancer. Expansion of the current eligibility criteria should be considered, though prospective validation is needed. Caution is required when considering APBI for patients with ILC.IMPLICATIONS FOR PRACTICE: In a large retrospective review of 946 patients with early breast cancer treated with partial mastectomy and APBI intracavitary brachytherapy, we demonstrate durable local control. Patients deemed unsuitable or high risk by the American Brachytherapy Society, American Society of Therapeutic Radiation Oncology, and European Society for Radiotherapy and Oncology guidelines were not at increased risk for IBTR, suggesting that expansion of the current criteria should be considered. Importantly, however, our results demonstrate that caution should be taken when considering APBI for patients with invasive lobular carcinoma, as these patients had relatively high risk for IBTR (10-year IBTR 14%).PMID:34516030 | DOI:10.1002/onco.13980
Source: The Oncologist - Category: Cancer & Oncology Authors: Source Type: research